Advanced Malignant Pleural or Peritoneal Mesothelioma Clinical Trial
— TALAMESOOfficial title:
A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients
Malignant mesothelioma is an invasive neoplasm that arises from mesothelium that lines
several organs. Common primary sites of origin of mesotheliomas are the pleura (malignant
pleural mesothelioma: 85%) and peritoneum (malignant peritoneal mesothelioma 15%), and rarely
the pericardium and tunica vaginalis.
The standard of care recommended for malignant pleural mesotheliomas (MPM) is palliative
chemotherapy based on a doublet of platinum salt and an anti-folate. The median survival of
patients with pleural MPM is around 8 months with best supportive care only, 12 to 19 months
when systemic chemotherapy is used with or without anti-angiogenic agents or targeted
therapy. There is an unmet need for innovative approaches in pleural mesotheliomas.
Malignant peritoneal mesothelioma is an aggressive neoplasm that arises from the lining
mesothelial cells of the peritoneum and spreads extensively within the confines of the
abdominal cavity. Cytoreductive surgery (CRS) followed by hyperthermic intraoperative
peritoneal perfusion with chemotherapy (HIPEC) is the standard curative approach when it is
possible, with respect to peritoneal carcinomatosis extend. When the cytoreductive surgery is
impossible, the common strategy is to prescribe systemic chemotherapy, with the objective of
downsizing tumor lesions for potential subsequent CRS. The standard strategy based on
cisplatin - pemetrexed combination regimen has been extrapolated from pleural mesothelioma
management principles.
Genomic landscape of mesotheliomas is now well described. Pleural and peritoneal malignant
mesotheliomas harbor closed genomic instability.
Strategies based on maintenance-based treatments with Poly (ADP-ribose) polymerase (PARP)
inhibitors, especially olaparib, niraparib and talazoparib, have been shown effective in
ovarian cancer patients, thereby leading to their approvals. The benefit has been mainly
observed in patients with homologous recombination deficiencies (HRD), but also in all-comers
patients in a lesser extent. It is thought that HRD induces addiction of cancer cells to
PARP, thereby leading to cell death in the presence of PARP inhibitors.
As a consequence, given the prevalence of HRD, through BAP-1 mainly, in mesotheliomas,
maintenance treatment with PARP-inhibitor in malignant mesothelioma patients without any
progressive disease after 4 to 6 cycles of platinum-based chemotherapy may be associated with
increased progression free survival, as it was shown in ovarian cancer patients.
TALAMESO aims to evaluate the efficacy of talazoparib maintenance treatment given for maximum
2 years following 4 to 6 cycles of platinum-based first line chemotherapy in terms of
proportion of patients progression free 6 months after starting the maintenance, and
progression-free survival, in patients with advanced malignant pleural (cohort A) or
peritoneal (cohorts B1 and B2) mesotheliomas.
Cohorts B1 and B2 are meant to confirm that talazoparib can increase progression free
survival in both patient populations with non-resected or incompletely resected disease
(cohort B1) or with completely resected disease (cohort B2).
TALAMESO is an open-label phase II trial with 3 independent cohorts (Fleming's single-stage)
including patients with advanced malignant pleural (cohort A) or peritoneal (cohort B1 and
B2) mesotheliomas without any sign of disease progression after 4 to 6 cycles of
platinum-based chemotherapy (including minimum 1 cycle of pemetrexed).
| Status | Not yet recruiting |
| Enrollment | 40 |
| Est. completion date | October 1, 2024 |
| Est. primary completion date | March 1, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients older than 18 years old - Patients with Eastern Cooperative Oncology Group (ECOG) performance status =2 - Histologically - or cytologically - confirmed malignant mesotheliomas: epithelioid, sarcomatoid, biphasic - Developed from pleura (cohort A) or from peritoneum (cohorts B1 and B2) - Previously treated with first-line platinum based-chemotherapy (including minimum one cycle of pemetrexed) for 4 to 6 cycles, with no sign of disease progression during chemotherapy. - No previous treatment with bevacizumab and PARP inhibitor - Minimum 6 weeks and maximum 8 weeks interval between last chemotherapy cycle and talazoparib start - For pleural mesotheliomas (cohort A), primary or interval debulking surgery with or without hyperthermic intrapleural or intrathoracic chemotherapy (HITHOC) will be authorized, in the case of non-complete cytoreductive surgery only - For peritoneal mesotheliomas - In cohort B1, primary or interval debulking surgery ± hyperthermic intraperitoneal chemotherapy (HIPEC) will be authorized in the case of non-complete cytoreductive surgery (CC2 or CC3) only. This cohort will also include patients with non-operated diseases - In cohort B2, complete macroscopic (CC0 or CC1) primary or interval debulking surgery ± HIPEC will be required. Intraperitoneal treatment with pressurized intraperitoneal aerosol chemotherapy sessions (PIPAC) are not allowed. - Measurable or non-measurable (but radiologically evaluable) disease as per modified RECIST version 1.1 on computed tomography (CT) scan (within 28 days of talazoparib initiation) - Availability at the study site of a representative FFPE tumor sample in a block or at least 30 unstained slides from biopsy or surgery specimen, aged less than 6 months. - Patients with adequate bone marrow function measured within 28 days prior to administration of study treatment as defined below: - Absolute neutrophil count =1.0 x 109 /L - Platelet count =50 x 109 /L - Haemoglobin =8.0 g/dL (may have been blood transfused) - Patients with adequate renal function: - Calculated Glomerular Filtration Rate (GFR) =30 ml/min/1.73 m2 according to CKD-EPI formula - Patients with adequate hepatic function - Total bilirubin = 1 × upper limit of normal [ULN] and aspartate aminotransferase (AST) > ULN - Total bilirubin > 1.0 to1.5 × ULN and any AST - Patients must have a life expectancy =16 week. - Confirmation of non-childbearing status (pregnancy test) for women of childbearing potential. - A highly effective method of contraception is required for female patients during treatment of talazoparib, and for at least 7 months after completing therapy. Advise male patients with female partners of reproductive potential and pregnant partners to use a condom, during treatment with talazoparib and for at least 4 months after the final dose. - Patients who gave its written informed consent to participate to the study. - Patients affiliated to a social insurance regime. - Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Exclusion Criteria: - Uncontrolled intercurrent illness, including but not limited to, such as congestive heart failure; respiratory distress; liver failure; allergy, or psychiatric illness/social situations that would limit compliance with study requirement according to the investigator, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent. - Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for =5 years. - All subjects with brain metastases or meningeal involvement. - Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 6 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug. - Persistent toxicities (CTCAE =grade 2) with the exception of alopecia and sensory neuropathy, caused by previous cancer therapy. - Treatment with other investigational agents. - Bowel occlusive syndrome, inflammatory bowel disease, immune colitis, or other gastro-intestinal disorder that does not allow oral medication such as malabsorption. - Known severe hypersensitivity reactions to PARP inhibitors. - Known HIV or AIDS related illness. - Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive). - Treatment with oral anticoagulant anti-vitamin K such Coumadin® - Prior organ transplantation, including allogeneic stem cell transplantation (excluding autologous bone marrow transplant). - Patients under guardianship. - Women who are breastfeeding (during treatment with talazoparib and for at least 1 month after the final dose) - Participation in other interventional clinical research that may interfere with the experimental drugs efficacy. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Non-progression proportion | The non-progression proportion is defined as the proportion of patients free of progression 6 months after talazoparib start. Disease progression will be based on (i) tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, ii) non-equivocal clinical symptom of disease progression according to the investigator; (iii) death related to disease progression. | 6 month after starting talazoparib | |
| Secondary | Progression free survival | The Progression-Free Survival (PFS) is defined as the time from inclusion to (1) first documented disease progression or death related to disease progression, whichever occurs first or, (2) end of follow-up. | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one.) | |
| Secondary | Progression free-survival based on RECIST 1.1 criteria | The Progression-Free Survival (PFS) is defined as the time from inclusion to first documented disease progression or death related to disease progression, whichever occurs first or, end of follow-up. Disease progression will be based on tumor assessment made by the investigators according to the RECIST 1.1 criteria and/or, non-equivocal clinical symptom of disease progression according to the investigator, and/or death related to disease progression. | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | |
| Secondary | Progression free-survival based on mRECIST criteria | The Progression-Free Survival (PFS) is defined as the time from inclusion to first documented disease progression or death related to disease progression, whichever occurs first or, end of follow-up. Disease progression will be based on tumor assessment made by the investigators according to the mRECIST criteria and/or, non-equivocal clinical symptom of disease progression according to the investigator, and/or death related to disease progression. | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | |
| Secondary | Overall Survival | The Overall Survival (OS) will be estimated from the date of inclusion to the date of death or to the end of follow-up. | Patients will be followed until the end of the study for collect date on progression and date of eventually death : .25 month for the latest enrolled patient to 49 months for the first one. | |
| Secondary | Safety, treatment-related adverse events | treatment-related adverse events are defined as the nature, number and grade of adverse events observed throughout the study and assessed using NCI-CTCAE v.5.0 criteria. | 6 weeks after the last experimental treatment for the latest enrolled patient |